NASDAQ:CLRB Cellectar Biosciences (CLRB) Stock Price, News & Analysis $3.20 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.24 +0.04 (+1.25%) As of 05/22/2026 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cellectar Biosciences Stock (NASDAQ:CLRB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cellectar Biosciences alerts:Sign Up Key Stats Today's Range$3.11▼$3.2950-Day Range$2.50▼$3.5352-Week Range$2.43▼$20.60Volume139,531 shsAverage Volume3.03 million shsMarket Capitalization$25.57 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingModerate Buy Company Overview Cellectar Biosciences, Inc. is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy. Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma. In addition to its therapeutic pipeline, Cellectar has developed CLR 1501 and CLR 1502, fluorescent and near‐infrared imaging probes that enhance intraoperative tumor detection and surgical guidance. These imaging agents are intended to help surgeons distinguish cancerous tissue from healthy tissue in real time. Founded in 2007 and headquartered in Madison, Wisconsin, Cellectar Biosciences conducts its research and development primarily in the United States. Preclinical and clinical studies have demonstrated the selective uptake and prolonged retention of its PDC compounds in tumor cells, supporting the potential of its platform across a range of oncologic indications. The company collaborates with academic centers and contract research organizations to advance its clinical programs. Under the leadership of President and Chief Executive Officer Will Berry, Cellectar Biosciences is advancing its pipeline and engaging with regulatory agencies to support future product commercialization. The company continues to explore strategic partnerships and funding opportunities to further develop its PDC technology for both therapeutic and diagnostic applications in oncology.AI Generated. May Contain Errors. Read More Cellectar Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreCLRB MarketRank™: Cellectar Biosciences scored higher than 83% of companies evaluated by MarketBeat, and ranked 96th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingCellectar Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCellectar Biosciences has a consensus price target of $11.00, representing about 243.8% upside from its current price of $3.20.Amount of Analyst CoverageCellectar Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Cellectar Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cellectar Biosciences are expected to grow in the coming year, from ($2.34) to ($1.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectar Biosciences is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectar Biosciences is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectar Biosciences has a P/B Ratio of 9.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cellectar Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.57% of the float of Cellectar Biosciences has been sold short.Short Interest Ratio / Days to CoverCellectar Biosciences has a short interest ratio ("days to cover") of 1.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectar Biosciences has recently decreased by 15.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCellectar Biosciences does not currently pay a dividend.Dividend GrowthCellectar Biosciences does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Cellectar Biosciences this week, compared to 3 articles on an average week.Search Interest8 people have searched for CLRB on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Cellectar Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Cellectar Biosciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $49,997.00 in company stock, which represents 0.1955% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Cellectar Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,997.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders5.04% of the stock of Cellectar Biosciences is held by insiders.Percentage Held by Institutions16.41% of the stock of Cellectar Biosciences is held by institutions.Read more about Cellectar Biosciences' insider trading history. Receive CLRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLRB Stock News HeadlinesCellectar Biosciences (NASDAQ:CLRB) Stock Price Crosses Below 200 Day Moving Average - What's Next?May 23 at 4:02 AM | americanbankingnews.comCellectar Biosciences (CLRB) price target decreased by 25.00% to 10.71May 14, 2026 | msn.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 26 at 1:00 AM | Porter & Company (Ad)Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...May 14, 2026 | finance.yahoo.comCellectar plans Phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027May 14, 2026 | seekingalpha.comCellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comCellectar Biosciences Reports Positive 12-Month Data for Iopofosine I 131 in Relapsed/Refractory Waldenström Macroglobulinemia and Secures $140 Million Financing for Confirmatory StudyMay 14, 2026 | quiverquant.comQInsider Buying: Cellectar Biosciences (NASDAQ:CLRB) CEO Purchases 8,680 Shares of StockMay 12, 2026 | insidertrades.comSee More Headlines CLRB Stock Analysis - Frequently Asked Questions How have CLRB shares performed this year? Cellectar Biosciences' stock was trading at $2.95 at the start of the year. Since then, CLRB shares have increased by 8.5% and is now trading at $3.20. How were Cellectar Biosciences' earnings last quarter? Cellectar Biosciences, Inc. (NASDAQ:CLRB) posted its earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, topping the consensus estimate of ($1.89) by $0.56. Read the conference call transcript. When did Cellectar Biosciences' stock split? Cellectar Biosciences shares reverse split on Friday, July 22nd 2022.The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Cellectar Biosciences' major shareholders? Cellectar Biosciences' top institutional shareholders include Sequoia Financial Advisors LLC (0.44%). Insiders that own company stock include Jarrod Longcor, James V Caruso, Chad J Kolean and John Neis. View institutional ownership trends. How do I buy shares of Cellectar Biosciences? Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cellectar Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectar Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), HudBay Minerals (HBM), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and Company Calendar Last Earnings5/14/2026Today5/26/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CLRB's financial health is in the Red zone, according to TradeSmith. CLRB has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLRB CIK1279704 Webwww.cellectar.com Phone(608) 441-8120Fax608-441-8121Employees10Year FoundedN/APrice Target and Rating Average Price Target for Cellectar Biosciences$11.00 High Price Target$11.00 Low Price Target$11.00 Potential Upside/Downside+243.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($6.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-349.24% Return on Assets-153.18% Debt Debt-to-Equity RatioN/A Current Ratio1.90 Quick Ratio1.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book9.14Miscellaneous Outstanding Shares7,990,000Free Float7,589,000Market Cap$25.57 million OptionableNo Data Beta0.43 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CLRB) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredMy crisis of conscienceEmmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...Porter & Company | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLRB Stock Alerts